Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

Steven E. Kahn, M.B., Ch.B., Steven M. Haffner, M.D., Mark A. Heise, Ph.D., William H. Herman, M.D., M.P.H., Rury R. Holman, F.R.C.P., Nigel P. Jones, M.A., Barbara G. Kravitz, M.S., John M. Lachin, Sc.D., M. Colleen O'Neill, B.Sc., Bernard Zinman, M.D., F.R.C.P.C., Giancarlo Viberti, M.D., F.R.C.P., for the ADOPT Study Group

Study Overview

This double-blind, randomized, controlled trial evaluated rosiglitazone, metformin, and glyburide as an initial treatment in patients with type 2 diabetes

Rosiglitazone reduced the risk of treatment failure (the primary outcome) by 32% as compared with metformin and by 63% as compared with glyburideThe potential risks, benefits, and costs of these medications

should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes

Enrollment and Outcomes

Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

Baseline Characteristics of the Patients* - Part I

Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

Baseline Characteristics of the Patients* - Part II

Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

Kaplan-Meier Estimates of the Cumulative Incidence of Monotherapy Failure at 5 Years

Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

Hazard Ratio for Monotherapy Failure in the Rosiglitazone Group, as Compared with the Metformin and Glyburide

Groups in Key Subgroups

Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

Fasting Plasma Glucose (Panel A), Glycated Hemoglobin (Panel B), Insulin Sensitivity (Panel C), β-Cell Function (Panel D), over Time,

According to Treatment Group

Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

Weight (Panel E), Waist Circumference (Panel F), Hip Circumference (Panel G),

and Waist-to-Hip Ratio (Panel H) over Time, According to Treatment Group

Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

Adverse Events, Laboratory Assessment, Concomitant Use of Cardiovascular Drugs,

Hospitalization, and Death* - Part I

Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

Adverse Events, Laboratory Assessment, Concomitant Use of Cardiovascular Drugs,

Hospitalization, and Death* - Part II

Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

Rate of Fractures

Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43